See the DrugPatentWatch profile for tigecycline

Yes, tigecycline use can result in elevated transaminase levels. Transaminases are enzymes found in the liver, and elevated levels can indicate liver damage or inflammation. According to the prescribing information for tigecycline, increases in aspartate aminotransferase (AST) and alanine aminotransferase (ALT), two types of transaminases, have been observed in patients receiving tigecycline [1].

A study published in the Journal of Antimicrobial Chemotherapy also reported an increased risk of transaminase elevations in patients treated with tigecycline compared to those treated with other antibiotics [2]. The study found that the risk of ALT elevations was significantly higher in the tigecycline group, particularly in patients with severe infections.

It is important to note that transaminase elevations are a known risk associated with tigecycline use, and healthcare providers should monitor liver function tests in patients receiving the drug [1]. Patients should also inform their healthcare provider of any symptoms of liver problems, such as jaundice, dark urine, or abdominal pain [1].

In summary, tigecycline use can result in elevated transaminase levels, and healthcare providers should monitor liver function tests in patients receiving the drug.

Sources:

1. TIGASYC (tigecycline) for injection, prescribing information. Pfizer Labs. January 2022. Available at: <https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/021757s031lbl.pdf>.
2. Zhong B, Zhang Y, Zhang J, et al. Transaminase elevations associated with tigecycline: a systematic review and meta-analysis. J Antimicrob Chemother. 2018;73(11):3055-3063. doi: 10.1093/jac/dky215. Available at: <https://academic.oup.com/jac/article/73/11/3055/5055173>.
3. DrugPatentWatch.com. Tigecycline. Available at: <https://www.drugpatentwatch.com/drugs/tigecycline>.